D75.828
Other heparin-induced thrombocytopenia syndrome
Clinical Classification Guidelines
Inclusion Terms
- Autoimmune heparin-induced thrombocytopenia syndrome
- Delayed-onset heparin-induced thrombocytopenia
- Persisting heparin-induced thrombocytopenia
Medical Intelligence & Overview
Other Heparin-Induced Thrombocytopenia Syndrome (HIT) represented by ICD-10 code D75.828, is a rare but serious immune-mediated condition that can develop after exposure to heparin, a common blood thinner. Unlike typical heparin-induced thrombocytopenia, this form can occur with delayed onset or persist beyond initial treatment, requiring careful recognition and management. It involves an immune response leading to the reduction of platelets and a heightened risk of blood clots. Understanding its causes, symptoms, and diagnosis can help anticipate and identify this condition promptly.
Causes & Symptoms
Clinical Causes: Recent or ongoing exposure to heparin, especially unfractionated or low molecular weight heparin Autoimmune reactions triggered by heparin therapy leading to the production of antibodies that target platelets Delayed-onset responses that can occur days or weeks after stopping heparin Persistence of the immune response even after cessation of heparin therapy
Key Symptoms: Sudden decrease in platelet count (thrombocytopenia) Development of blood clots in veins or arteries, leading to complications such as deep vein thrombosis or pulmonary embolism Pain, swelling, or redness at sites of thrombosis Skin changes like redness or discoloration Fever or chills, sometimes indicating an immune response In some cases, symptoms of organ dysfunction if clots impair blood flow to vital organs
Diagnostic & Treatment
Diagnosis Path: Diagnosing other heparin-induced thrombocytopenia involves a combination of clinical evaluation and laboratory tests. Key steps include: - Monitoring platelet counts during and after heparin therapy, especially if symptoms suggestive of clotting or bleeding occur. - Conducting specific antibody tests, such as ELISA or serotonin release assays, to detect antibodies against platelet factor 4 (PF4) complexed with heparin. - Imaging studies like ultrasound or scans to identify blood clots. - Ruling out other causes of thrombocytopenia and thrombosis. Early diagnosis is vital to prevent serious complications due to clot formation.
Treatment Protocols: Management of other heparin-induced thrombocytopenia focuses on stopping heparin therapy immediately and initiating alternative anticoagulation to prevent or treat blood clots. Typical treatment options include: - Discontinuation of all forms of heparin. - Use of non-heparin anticoagulants such as argatroban, bivalirudin, or fondaparinux. - Avoiding platelet transfusions unless there is life-threatening bleeding. - Regular monitoring of platelet counts and clotting parameters. - Treatment of any existing blood clots with appropriate anticoagulants. - Supportive care and management of complications as needed. Since the condition involves immune responses, some patients may require additional therapies to suppress immune activity, as recommended by healthcare providers.
Clinical Advice & FAQs
Billing Guidance
Is D75.828 a billable ICD-10 code?
Yes, D75.828 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D75.828?
Clinical documentation must specify the nature of Other heparin-induced thrombocytopenia syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference